Loading…
← CockpitCompetitor Analysis › 6547.TWO Medigen Vaccine Biologics Corp.Open in the cockpit ↗

Medigen Vaccine Biologics Corp.6547.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Biotechnology
Momentum neutral 50
Mkt cap
$424M
US dollars, full cap
Free float
73%
of shares outstanding
$/day
$2.93M
20-day average traded
Fwd P/E
170.0×
forward earnings
ROIC−WACC
-6.1 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
114 days
12 Mar 2027
Close · TWDNT$44.10
1D-2.0%
1W-4.8%
1M-16.3%
3M-14.4%
6M-7.9%
YTD+16.8%
1Y+26.5%
ATR %4.8%
52w lowhigh38.9% off high

What Medigen Vaccine Biologics does

No business profile yet.

Medigen Vaccine Biologics at a glance

Size Medigen Vaccine Biologics (6547.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $424M, the 487th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$44.10 on 18 Nov 2026.

Performance Over six months the shares fell 7.9%, against -22.0% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 44.4% over the last twelve months (peer median +1.7%); the operating margin is -4.5% (peer median -12.8%).

Valuation It trades at 170.0× forward earnings against a peer median of 26.2× (most expensive of 6).

Capital Return on invested capital runs 6.1 points below its cost of capital (5.0% WACC).

Next results Next results expected around 12 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 20266547.TWO 90Peer median 78
Six months, rebased to 100: Medigen Vaccine Biologics against the median of its 20 peers (local-currency closes).

Medigen Vaccine Biologics financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$859MNT$613MNT$606MNT$390MNT$365M
Revenue growth—+1%+55%+7%—
Gross profitNT$447MNT$312MNT$332MNT$221M-NT$221M
EBITDANT$110M-NT$124M-NT$9.23M-NT$1.08B-NT$1.41B
Net income-NT$34.9M-NT$282M-NT$80.5M-NT$1.16B-NT$1.47B
Free cash flow-NT$428M-NT$99.7MNT$6.46M-NT$516M-NT$1.24B
Capital expenditureNT$387MNT$51.8MNT$35.0MNT$41.0MNT$140M
Total debtNT$540MNT$283MNT$339MNT$1.97BNT$1.98B

Quarterly statements and history in the cockpit →

Medigen Vaccine Biologics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%68831767122509PRTA476830CADL456160688163EPRX17896882386037390007106998IRLA3378ARVN658911676880986547.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. Medigen Vaccine Biologics is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%0×50×100×150×67122509178911676547.TWORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Medigen Vaccine Biologics is the large dot.

Medigen Vaccine Biologics competitors and peer comparison

How Medigen Vaccine Biologics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Medigen Vaccine Biologics against its 20 peers (data as of 18 Nov 2026)
Measure6547.TWOPeer medianRank in peer set
1-month return-16.3%-12.4%8th lowest of 21
6-month return-7.9%-22.0%7th highest of 21
Distance from 52-week high-38.9%-43.6%9th highest of 21
Revenue growth (TTM)+44.4%+1.7%6th highest of 17
Operating margin-4.5%-12.8%8th highest of 17
Forward P/E170.0×26.2×most expensive of 6
ROIC minus cost of capital-6.1 pp-11.2 pp7th highest of 16
Net debt / EBITDA-12.9×-2.6×least indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Medigen Vaccine Biologics 6547.TWOTaiwan$424M-8%+44%-5%170.0×n/an/a
Shanghai ZJ Bio-Tech 688317.SSChina$422M-22%-10%-72%n/a4.0%-62.3%
Ever Supreme Bio Technology 6712.TWOTaiwan$427M+11%+13%47%26.2×5.3%+70.5%
Qyuns Therapeutics 2509.HKHong Kong$428M-11%+230%56%10.2×-19.5%n/a
Prothena PRTAUnited States$429M-11%+347%-73%n/an/an/a
Rznomics 476830.KSSouth Korea$418M-76%-65%-1,112%n/an/an/a
Candel Therapeutics CADLUnited States$417M-31%n/an/an/an/an/a
G2GBIO 456160.KSSouth Korea$416M-53%-45%-2,884%n/an/an/a
Shanghai Serum Bio-Technology 688163.SSChina$416M-34%-1%26%n/an/an/a
Eupraxia Pharmaceuticals EPRX.TOCanada$416M+1%n/an/an/an/an/a
Scinopharm Taiwan 1789.TWTaiwan$435M-2%-5%-4%39.4×2.1%+0.5%
Shanghai Obio Technology (Group) 688238.SSChina$414M-5%+20%-79%n/an/an/a
Qingdao Vland Biotech 603739.SSChina$437M-24%+5%7%33.9×7.7%+7.3%
Berry Genomics 000710.SZChina$439M-17%-2%-24%n/an/an/a
Edding Genor 6998.HKHong Kong$410M-35%+1,418%26%n/a-15.3%+197.3%
IRulya Therapeutics IRLAUnited States$440M+88%n/an/an/an/an/a
Hanx Biopharmaceuticals (Wuhan) 3378.HKHong Kong$409M-24%n/an/an/an/an/a
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a
EirGenix 6589.TWTaiwan$444M+15%+58%-51%n/an/an/a
Jacobio Pharmaceuticals 1167.HKHong Kong$404M-24%+286%68%5.7×-18.8%-36.1%
Shanghai Shen Lian Biomedical 688098.SSChina$402M-22%-17%-16%n/an/an/a

Questions

Which companies are Medigen Vaccine Biologics's closest peers?
The cockpit's peer set: Shanghai ZJ Bio-Tech (688317.SS), Ever Supreme Bio Technology (6712.TWO), Qyuns Therapeutics (2509.HK), Prothena (PRTA), Rznomics (476830.KS), Candel Therapeutics (CADL), G2GBIO (456160.KS), Shanghai Serum Bio-Technology (688163.SS).
Is Medigen Vaccine Biologics expensive compared with its peers?
On forward p/e it trades at 170.0× against a peer median of 26.2×, most expensive of 6 in its peer set.
How has Medigen Vaccine Biologics stock performed?
Over six months to 18 Nov 2026 the shares returned -7.9% against -22.0% for the median peer; over one year +26.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.